Phase Ib / II Study of Anlotinib Combined With Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Anlotinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 17 Sep 2018 Planned primary completion date changed from 15 Aug 2021 to 22 Aug 2021.
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 27 Aug 2018 New trial record